Physician profile
Robert Michael Galbraith
NPI 1609802859
$3,176.77
in general payments reported to CMS, 2019-2025
26 companies · $168 in 2025
The $168 reported for 2025 was more than what a typical Sports Medicine (Family Medicine) provider received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,316 · 2022: $573 · 2023: $613 · 2024: $507 · 2025: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,287.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pylant Medical | $1,225.88 | 2021-2023 | |
| Glaxosmithkline, LLC. | $399.34 | 2021-2024 | Trelegy Ellipta, Nucala, Arexvy |
| Lilly USA, LLC | $203.49 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $175.26 | 2024-2025 | Jardiance |
| Novo Nordisk INC | $139.88 | 2022-2025 | Wegovy |
| Abbvie INC. | $119.07 | 2022-2023 | |
| Corium, LLC | $108.56 | 2023 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $104.41 | 2021-2023 | Austedo Xr |
| Bioventus LLC | $104.27 | 2022-2024 | Durolane, Durolane |
| Pfizer INC. | $90.61 | 2024 | |
| Merck Sharp & Dohme LLC | $72.24 | 2022-2023 | Belsomra, Steglatro |
| Exact Sciences Corporation | $62.07 | 2023-2025 | Cologuard Collection Kit |
| Jazz Pharmaceuticals INC. | $56.73 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.98 | 2022-2023 | Xifaxan |
| Nevro Corp. | $49.94 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $31.20 | 2022-2023 | Orthovisc, Monovisc |
| Bayer Healthcare Pharmaceuticals INC. | $28.33 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.34 | 2022 | |
| Corcept Therapeutics | $21.12 | 2024 | Korlym |
| Pacira Pharmaceuticals Incorporated | $17.86 | 2023 | Exparel, Zilretta, Iovera |
| Kowa Pharmaceuticals America, INC. | $16.82 | 2023 | Seglentis |
| Irhythm Technologies, INC. | $16.28 | 2022 | |
| Allergan, INC. | $16.24 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $15.90 | 2021 | |
| Abbott Laboratories | $14.96 | 2025 | Freestyle Libre 3 |
| Orthofix Medical, INC. | $8.99 | 2025 | Physio-Stim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Galbraith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.